CN101842354A - 儿茶酚胺衍生物及其前药 - Google Patents

儿茶酚胺衍生物及其前药 Download PDF

Info

Publication number
CN101842354A
CN101842354A CN200880113440A CN200880113440A CN101842354A CN 101842354 A CN101842354 A CN 101842354A CN 200880113440 A CN200880113440 A CN 200880113440A CN 200880113440 A CN200880113440 A CN 200880113440A CN 101842354 A CN101842354 A CN 101842354A
Authority
CN
China
Prior art keywords
benzo
compound
compound according
pharmaceutically acceptable
octahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880113440A
Other languages
English (en)
Chinese (zh)
Inventor
M·约尔根森
B·邦-安德森
A·皮施尔
N·莫克
J·拉森
H·V·维克斯特伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39877715&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101842354(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of CN101842354A publication Critical patent/CN101842354A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/08—Aza-anthracenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Portable Nailing Machines And Staplers (AREA)
  • Indole Compounds (AREA)
CN200880113440A 2007-08-31 2008-08-28 儿茶酚胺衍生物及其前药 Pending CN101842354A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200701250 2007-08-31
DKPA200701250 2007-08-31
PCT/DK2008/050215 WO2009026935A1 (en) 2007-08-31 2008-08-28 Catecholamine derivatives and prodrugs thereof

Publications (1)

Publication Number Publication Date
CN101842354A true CN101842354A (zh) 2010-09-22

Family

ID=39877715

Family Applications (3)

Application Number Title Priority Date Filing Date
CN200880113440A Pending CN101842354A (zh) 2007-08-31 2008-08-28 儿茶酚胺衍生物及其前药
CN201710269745.1A Pending CN107253956A (zh) 2007-08-31 2008-08-28 用于治疗帕金森症的儿茶酚胺衍生物及其制备方法
CN200880023124A Pending CN101687878A (zh) 2007-08-31 2008-08-28 可用于治疗帕金森症的儿茶酚胺衍生物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201710269745.1A Pending CN107253956A (zh) 2007-08-31 2008-08-28 用于治疗帕金森症的儿茶酚胺衍生物及其制备方法
CN200880023124A Pending CN101687878A (zh) 2007-08-31 2008-08-28 可用于治疗帕金森症的儿茶酚胺衍生物

Country Status (29)

Country Link
EP (4) EP2662358A1 (cg-RX-API-DMAC7.html)
JP (4) JP2010536890A (cg-RX-API-DMAC7.html)
KR (3) KR20150115963A (cg-RX-API-DMAC7.html)
CN (3) CN101842354A (cg-RX-API-DMAC7.html)
AR (2) AR068045A1 (cg-RX-API-DMAC7.html)
AU (2) AU2008291426B2 (cg-RX-API-DMAC7.html)
BR (2) BRPI0815894A2 (cg-RX-API-DMAC7.html)
CA (2) CA2697688A1 (cg-RX-API-DMAC7.html)
CL (2) CL2008002564A1 (cg-RX-API-DMAC7.html)
CO (2) CO6270232A2 (cg-RX-API-DMAC7.html)
CY (1) CY1117326T1 (cg-RX-API-DMAC7.html)
DK (1) DK2197883T3 (cg-RX-API-DMAC7.html)
EA (2) EA018011B1 (cg-RX-API-DMAC7.html)
ES (1) ES2557485T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20151334T1 (cg-RX-API-DMAC7.html)
HU (1) HUE025882T2 (cg-RX-API-DMAC7.html)
IL (1) IL203080A (cg-RX-API-DMAC7.html)
MX (1) MX2010002210A (cg-RX-API-DMAC7.html)
MY (2) MY179527A (cg-RX-API-DMAC7.html)
NZ (2) NZ582379A (cg-RX-API-DMAC7.html)
PL (1) PL2197883T3 (cg-RX-API-DMAC7.html)
PT (1) PT2197883E (cg-RX-API-DMAC7.html)
RS (1) RS54470B1 (cg-RX-API-DMAC7.html)
SG (1) SG184711A1 (cg-RX-API-DMAC7.html)
SI (1) SI2197883T1 (cg-RX-API-DMAC7.html)
TW (2) TWI404702B (cg-RX-API-DMAC7.html)
UA (2) UA98804C2 (cg-RX-API-DMAC7.html)
WO (2) WO2009026935A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA200909191B (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113727974A (zh) * 2019-05-21 2021-11-30 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药
CN116568672A (zh) * 2020-11-17 2023-08-08 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI404702B (zh) * 2007-08-31 2013-08-11 Lundbeck & Co As H 兒茶酚胺衍生物和其前藥
WO2009156458A1 (en) * 2008-06-27 2009-12-30 H. Lundbeck A/S Novel phenolic and catecholic amines and prodrugs thereof
US8067410B2 (en) 2008-06-27 2011-11-29 H. Lundbeck A/S Phenolic and catecholic amines and prodrugs thereof
TW201035054A (en) * 2009-02-27 2010-10-01 Lundbeck & Co As H Methods of administering (4aR, 10aR)-1-n-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol and pharmaceutical compositions thereof
TW201036949A (en) * 2009-02-27 2010-10-16 Lundbeck & Co As H Treatment of dyskinesia related disorders
PT3713933T (pt) 2017-11-24 2026-05-19 H Lundbeck As Novos profrmacos de catecolamina para utilizao no tratamento de doena de parkinson
WO2020070099A1 (en) 2018-10-02 2020-04-09 H. Lundbeck A/S Administration of catecholamine prodrugs in combination with a 5-ht2b antagonist
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) * 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11104697B2 (en) * 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11111263B2 (en) * 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
JP7641234B2 (ja) 2019-05-21 2025-03-06 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
WO2020234275A1 (en) 2019-05-21 2020-11-26 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's diseases
EP3972600B1 (en) 2019-05-21 2026-02-18 H. Lundbeck A/S Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease
CN114478298B (zh) * 2020-11-12 2024-09-27 成都西岭源药业有限公司 一种造影剂碘佛醇的纯化方法
CN113620760A (zh) * 2021-09-07 2021-11-09 张家口思睿凯科技有限公司 一种电子盐反应液和不饱和芳香烃类化合物的还原方法
WO2025078574A1 (en) * 2023-10-12 2025-04-17 Integrative Research Laboratories Sweden Ab NOVEL ESTERS OF 1,2,3,4,4a,5,6,7,8,9,10,10a-DODECAHYDROBENZO[g]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997017326A1 (en) * 1995-11-10 1997-05-15 Novo Nordisk A/S Enantiomers of cis-benz[e]indole compounds, their preparation and utility as dopamine-d3 receptor selective agents

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080456A (en) * 1971-10-26 1978-03-21 Schering Aktiengesellschaft Diacylapomorphines
CH648300A5 (en) * 1979-06-22 1985-03-15 Sandoz Ag Phenanthrene derivatives and medicaments containing them
US4543256A (en) * 1982-03-17 1985-09-24 Northeastern University (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers
WO1990012574A1 (en) * 1989-04-25 1990-11-01 Northeastern University Dopamine agonist compounds
PT95142B (pt) * 1989-08-30 1997-05-28 Sankyo Co Processo para a preparacao de derivados indolobenzoquinolinicos com accao anti-arritmica
TW357143B (en) * 1995-07-07 1999-05-01 Novartis Ag Benzo[g]quinoline derivatives
CN1241998A (zh) * 1996-10-30 2000-01-19 伊莱利利公司 苯并[f]喹啉酮的合成
SE0102036D0 (sv) 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
SE0002934D0 (sv) * 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
AR030357A1 (es) * 2000-08-18 2003-08-20 Lundbeck & Co As H Derivados 4 -, 5 -, 6 - y 7-indol
US20050090518A1 (en) * 2003-10-24 2005-04-28 Nastech Pharmaceutical Company Inc. Method for treating parkinson's disease using apomorphine and apomorphine prodrugs
TWI404702B (zh) * 2007-08-31 2013-08-11 Lundbeck & Co As H 兒茶酚胺衍生物和其前藥

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997017326A1 (en) * 1995-11-10 1997-05-15 Novo Nordisk A/S Enantiomers of cis-benz[e]indole compounds, their preparation and utility as dopamine-d3 receptor selective agents

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AMANDA J. BRADBURY, ET AL.: "A COMPARISON OF DOPAMINE AGONIST ACTION TO INHIBIT LOCOMOTOR ACTIVITY AND TO INDUCE STEREOTYPED BEHAVIOUR IN THE MOUSE", 《EUROPEAN JOURNAL OF PHARMACOLOGY》 *
DANYANG LIU, ET AL.: "A novel synthesis and pharmacological evaluation of a potential dopamine D1/D2 agonist: 1-Propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diol", 《BIOORGANIC & MEDICINAL CHEMISTRY》 *
YOSHIHARU ITOH, ET AL.: "TL 333, A BENZHYDRO[G]QUINOLINE, STIMULATES BOTH D-I AND D-2 DOPAMINE RECEPTORS: IMPLICATIONS FOR THE SELECTIVITY OF LY 141865 TOWARDS THE D-2 RECEPTOR", 《EUROPEAN JOURNAL OF PHARMACOLOGY》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113727974A (zh) * 2019-05-21 2021-11-30 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药
CN113727974B (zh) * 2019-05-21 2025-01-07 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药
CN116568672A (zh) * 2020-11-17 2023-08-08 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药

Also Published As

Publication number Publication date
ES2557485T3 (es) 2016-01-26
EA018011B1 (ru) 2013-04-30
CO6260082A2 (es) 2011-03-22
KR20100051834A (ko) 2010-05-18
NZ582379A (en) 2011-08-26
TWI404702B (zh) 2013-08-11
EP2197883B1 (en) 2015-11-18
NZ583551A (en) 2012-07-27
SI2197883T1 (sl) 2016-01-29
HRP20151334T1 (hr) 2016-01-01
MY148948A (en) 2013-06-14
CL2008002558A1 (es) 2009-08-07
CN101687878A (zh) 2010-03-31
ZA201001422B (en) 2011-06-29
EP3009437A1 (en) 2016-04-20
WO2009026934A1 (en) 2009-03-05
AR068044A1 (es) 2009-10-28
AU2008291425A1 (en) 2009-03-05
MX2010002210A (es) 2010-03-17
UA98804C2 (ru) 2012-06-25
CA2691961C (en) 2013-12-17
TW200911752A (en) 2009-03-16
TW200914426A (en) 2009-04-01
UA97989C2 (uk) 2012-04-10
JP5548125B2 (ja) 2014-07-16
JP5802792B2 (ja) 2015-11-04
RS54470B1 (sr) 2016-06-30
JP2014148528A (ja) 2014-08-21
BRPI0815894A2 (pt) 2015-02-24
BRPI0813456A2 (pt) 2014-12-23
MY179527A (en) 2020-11-10
CN107253956A (zh) 2017-10-17
EA201070327A1 (ru) 2010-08-30
ZA200909191B (en) 2011-03-30
WO2009026935A1 (en) 2009-03-05
CA2691961A1 (en) 2009-03-05
EP2195291A1 (en) 2010-06-16
EA200971107A1 (ru) 2010-06-30
EA018413B1 (ru) 2013-07-30
PT2197883E (pt) 2016-02-02
JP2010536889A (ja) 2010-12-02
KR20100046111A (ko) 2010-05-06
CA2697688A1 (en) 2009-03-05
KR101597367B1 (ko) 2016-02-24
DK2197883T3 (en) 2016-01-11
AU2008291426B2 (en) 2013-01-31
PL2197883T3 (pl) 2016-03-31
AU2008291426A1 (en) 2009-03-05
IL203080A (en) 2014-11-30
AU2008291425B2 (en) 2012-12-06
JP2014111635A (ja) 2014-06-19
JP2010536890A (ja) 2010-12-02
EP2197883A1 (en) 2010-06-23
AR068045A1 (es) 2009-10-28
SG184711A1 (en) 2012-10-30
EP2662358A1 (en) 2013-11-13
CY1117326T1 (el) 2017-04-26
KR20150115963A (ko) 2015-10-14
CO6270232A2 (es) 2011-04-20
CL2008002564A1 (es) 2009-07-17
HUE025882T2 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
JP5802792B2 (ja) パーキンソン病の治療のために有用なカテコールアミン誘導体
US8129530B2 (en) Catecholamine derivatives and prodrugs thereof
JP2011525893A (ja) 新規のフェノールアミン類およびカテコールアミン類ならびにそのプロドラッグ
US20120196889A1 (en) Catecholamine derivatives and prodrugs thereof
HK1237782A1 (en) Catecholamine derivatives useful for the treatment of parkinson’s disease and method of preparing the same
HK1237782A (en) Catecholamine derivatives useful for the treatment of parkinson’s disease and method of preparing the same
HK1148737A (en) Catecholamine derivatives and prodrugs thereof
HK1142072A (en) Catecholamine derivatives useful for the treatment of parkinson's disease
HK1191333A (en) Catecholamine derivatives and prodrugs thereof
AU2013203089A1 (en) Catecholamine derivatives and prodrugs thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1148737

Country of ref document: HK

AD01 Patent right deemed abandoned

Effective date of abandoning: 20100922

C20 Patent right or utility model deemed to be abandoned or is abandoned
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1148737

Country of ref document: HK